Navigation Links
XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Date:12/10/2007

esented appear to be significantly more potent than A831 in the replicon assay.

A second poster presentation entitled "Pharmacologic Evaluation of Novel Small Molecule HCV Inhibitors Affecting NS5A-dependent Functions" describes the results of studies on the potency, specificity, toxicology and pharmacokinetics of the Company's lead HCV molecules. In these studies, when administered orally to rodents, the compounds demonstrated preferential accumulation in the liver in concentrations that were orders of magnitude above those required to block viral replication as predicted by the replicon assay, with half-lives consistent with a twice a day dosing regimen. Toxicology studies showed that the activity of these molecules was selective for HCV, with no apparent adverse effects on a range of human cell types or on rodents exposed to repeated high doses.

The small molecules being presented by the Company at the conference emerged from the Company's DOS program, aimed at discovering novel HCV inhibitors by applying a unique chemistry technology called Diversity Oriented Synthesis.

ABOUT HEPATITIS C VIRUS

There are approximately 3 million people infected with HCV in the U.S. alone. HCV infection significantly increases the infected person's risk of developing chronic liver disease, cirrhosis and liver cancer, and is the leading cause of liver transplantation in the Western World. HCV infection remains a major unmet medical need as the current standard of care (interferon-based therapy) achieves success in only 50% of patients infected with genotype 1 of the virus (genotype 1 affects 75% patients in the U.S.), and has significant side affects associated with it.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic ne
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ... agreement with Hitachi Koki of Japan ... North America . NuAire will utilize its network ... and Canada to offer assistance in application ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014   Evidera ... healthcare industry, announced that the Center for Drug Evaluation ... released its first draft qualification guidance document for a ... of Exacerbations of Chronic Pulmonary Disease Tool [EXACT] for ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
(Date:7/9/2014)... Chase Cancer Center paint a relatively optimistic picture of ... that have spread to the chest wall or skin, ... the skin, regardless of size and whether they have ... and called "locally advanced" tumors, suggesting that they ... poor survival. Locally advanced breast cancers of this and ...
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... and subjective, the human brain turns them into ... different senses, situations and even people, reports a ... , "We discovered that fine-grained patterns of neural ... the brain associated with emotional processing, act as ... feeling," says Anderson, associate professor of human development ...
(Date:7/9/2014)... 2014 There has been a sharp increase in ... Center using MyChart, the online, interactive service that allows ... their healthcare providers, schedule appointments, and renew prescriptions. , ... using MyChart each year increased five-fold, while ... than 10-fold, according to a study by Dr. ...
(Date:7/9/2014)... declines and extinctions around the world have been ... but new research from the National Institute for ... pathogen, ranavirus, may also contribute. , In ... ranavirus, which causes severe hemorrhage of internal organs ... of wood frogs if they are exposed to ...
Breaking Medicine News(10 mins):Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2
... From the many images sent home from foreign battlefields over ... their country,s combat-weary veterans as stark and often iconic scenes ... Washington State University (WSU) suggests that, for many U.S. veterans, ... of the balance of their lives. In research published ...
... vaccines There are several challenges to be ... boost the patient,s anticancer immune response, are to be ... the tumor protein to the patient,s immune system are ... and suppressive responses. But now, a team of researchers, ...
... HealthDay Reporter , MONDAY, Aug. 2 (HealthDay News) -- The ... household cleaning products have decreased almost by half since 1990, ... still being treated in U.S. emergency rooms every year for ... Bleach was the cleaning product most commonly associated with injury ...
... rates of healing according to the way they cope and ... a health psychologist at The University of Nottingham. The ... month has shown that the way patients cope with the ... heals or worsens. The work by Professor Kavita Vedhara ...
... hospitals in the United States have developed an advanced search ... radiologists and other physicians extract useful data from a patient,s ... according to an article in the August issue of the ... www.jacr.org ). "Even in its simplest implementation, the ...
... at the University of Rochester,s Laboratory for Laser Energetics blocks ... light is shined on its surface, and permits gas to ... is the first time that scientists have developed a membrane ... Eric Glowacki, a graduate student at the University,s Laboratory for ...
Cached Medicine News:Health News:Sociologist finds combat veterans face more lifelong socioeconomic challenges 2Health News:JCI online early table of contents: August 2, 2010 2Health News:JCI online early table of contents: August 2, 2010 3Health News:JCI online early table of contents: August 2, 2010 4Health News:JCI online early table of contents: August 2, 2010 5Health News:JCI online early table of contents: August 2, 2010 6Health News:Household Spray Cleaners Pose Greatest Danger to Toddlers 2Health News:Household Spray Cleaners Pose Greatest Danger to Toddlers 3Health News:Mind over matter? The psychology of healing 2Health News:Researchers develop advanced search tool to help physician's sort and retrieve vital EMR data 2Health News:Purple light means go, ultraviolet light means stop 2
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
Inquire...
Guaranteed leak-proof , Teflon coating is impervious to corrosive materials , Shock-resistant , NBS tolerances of accuracy , Thermometers are 225 mm long with an immersion length of 35 mm ...
... efficient refrigerator on the market today. The ... unit. The contoured drain channels away moisture ... walls are coated with a tough, baked-on ... door is reversible. The interior of the ...
Medicine Products: